News
The FDA expanded its approval of Moderna's RSV vaccine on Thursday to include adults under age 60 at increased risk of the ...
A U.S. government scientist who oversees the team responsible for collecting data on COVID-19 and RSV hospitalizations used ...
The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...
For the 2025-2026 respiratory viral season, Moderna intends to have mResvia available for both FDA-approved patient populations.
In the wake of Robert F. Kennedy Jr.’s abrupt revamp of the CDC’s Advisory Committee on Immunization Practices, details from the panel’s planned meeting next week are confirming many industry ...
The FDA approved mResvia for the prevention of RSV in people ages 18 to 59 years who are at increased risk for severe disease ...
Dr. Fiona Havers, who studied medicine at the University of Washington, says the wholesale dismissal of the CDC's scientific ...
The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...
Potential First-in-Class Respiratory Combination Vaccine Candidates SCB-1022 (RSV + hMPV) and SCB-1033 (RSV + hMPV + PIV3) Enter the Clinical Trial Stage -- ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results